Resultados de Búsqueda por Autor

1

artículo

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Publicado por
Francis, PA, Pagani, O, Fleming, GF, Walley, BA, Colleoni, M, Láng, I, Gómez, HL, Tondini, C, Ciruelos, E, Burstein, HJ, Bonnefoi, HR, Bellet, M, Martino, S, Geyer, CE, Goetz, MP, Stearns, V, Pinotti, G, Puglisi, F, Spazzapan, S, Climent, MA, Pavesi, L, Ruhstaller, T, Davidson, NE, Coleman, R, Debled, M, Buchholz, S, Ingle, JN, Winer, EP, Maibach, R, Rabaglio-Poretti, M, Ruepp, B, Di Leo, A, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group.

Publicado 2018

Enlace

Background: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials. Methods: Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy. Results: In SOFT, th...

2

artículo

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis...

Publicado por
Regan, MM, Walley, BA, Francis, PA, Fleming, GF, Láng, I, Gómez, HL, Colleoni, M, Tondini, C, Pinotti, G, Salim, M, Spazzapan, S, Parmar, V, Ruhstaller, T, Abdi, EA, Gelber, RD, Coates, AS, Goldhirsch, A, Pagani, O

Publicado 2017

Enlace

Background: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. Design and methods: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin. Breast cancer-free interval (BCFI) was compared between patients who received OFS concurrently with chemotherapy in TEXT (n = 1242) versus sequentially post-chemotherapy in SOFT (n = 630). Because timing of trial enrollment relative to adjuvant chemotherapy differed, w...

3

artículo

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230

Publicado por
Moore, HCF, Unger, JM, Phillips, KA, Boyle, F, Hitre, E, Moseley, A, Porter, DJ, Francis, PA, Goldstein, LJ, Gomez-Moreno, HL, Vallejos-Sologuren, CS, Partridge, AH, Dakhil, SR, Garcia, AA, Gralow, JR, Lombard, JM, Forbes, JF, Martino, S, Barlow, WE, Fabian, CJ, Minasian, LM, Meyskens, FL, Gelber, RD, Hortobagyi, GN, Albain, KS

Publicado 2019

Enlace

Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% ...

4

artículo

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Publicado por
Saha, P, Regan, MM, Pagani, O, Francis, PA, Walley, BA, Ribi, K, Bernhard, J, Luo, W, Gómez, HL, Burstein, HJ, Parmar, V, Torres, R, Stewart, J, Bellet, M, Perelló, A, Dane, F, Moreira, A, Vorobiof, D, Nottage, M, Price, KN, Coates, AS, Goldhirsch, A, Gelber, RD, Colleoni, M, Fleming, GF, SOFT TEXT Investigators, International Breast Cancer Study Group

Publicado 2017

Enlace

Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receivin...

5

objeto de conferencia

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

Publicado por
Pagani, O, Walley, BA, Fleming, G.F, Colleoni M, Láng I, Gomez H.L, Tondini C, Burstein H.J, Goetz M.P, Ciruelos E.M, Stearns V, Bonnefoi H.R, Martino S, Geyer C.E, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer E.P, Ruepp B, Loi S, Coates A.S, Gelber R.D, Goldhirsch A, Regan M.M, Francis P.A.

Publicado 2023

Enlace

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The combined analysis of SOFT-TEXT compared outcomes in 4,690 premenopausal women with estrogen/progesterone receptor-positive (ER/PgR+) early breast cancer randomly assigned to 5 years of exemestane + ovarian function suppression (OFS) versus tamoxifen + OFS. After a median follow-up of 9 years, exemestane + OFS significantly improved disease-free survival (DFS) and distant recurrence-free interval (DRFI), but not overall survival, compared with tamoxifen + OFS. We now rep...

6

artículo

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Publicado por
Cardoso, F, Paluch-Shimon, S, Senkus, E, Curigliano, G, Aapro, MS, André, F, Barrios, CH, Bergh, J, Bhattacharyya, GS, Biganzoli, L, Boyle, F, Cardoso, MJ, Carey, LA, Cortés, J, El Saghir, NS, Elzayat, M, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Gligorov, J, Haidinger, R, Harbeck, N, Hu, X, Kaufman, B, Kaur, R, Kiely, BE, Kim, SB, Lin, NU, Mertz, SA, Neciosup, SO, ffersen, BV, Ohno, S, Pagani, O, Prat, A, Penault-Llorca, F, Rugo, HS, Sledge, GW, Thomssen, C, Vorobiof, DA, Wiseman ,T, Xu, B, Norton, L, Costa, A, Winer, EP

Publicado 2020

Enlace

This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.

7

artículo

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Publicado por
El Bairi, K, Haynes, HR, Blackley, E, Fineberg, S, Shear, J, Turner, S, de Freitas, JR, Sur, D, Amendola, LC, Gharib, M, Kallala, A, Arun, I, Azmoudeh-Ardalan F, Fujimoto, L, Sua, LF, Liu, SW, Lien, HC, Kirtani, P, Balancin, M, El Attar, H, Guleria, P, Yang WShash, E, Chen, IC, Bautista, V, Do Prado Moura, JF, Rapoport, BL, Castaneda, C, Spengler, E, Acosta-Haab, G, Frahm, I, Sanchez, J, Castillo, M, Bouchmaa, N, Md Zin, RR, Shui, R, Onyuma, T, Yang, W, Husain, Z, Willard-Gallo, K, Coosemans, A, Perez, EA, Provenzano, E, Ericsson, PG, Richardet, E, Mehrotra, R, Sarancone, S, Ehinger, A, Rimm, DL, Bartlett, JMS, Viale, G, Denkert, C, Hida, AI, Sotiriou, C, Loibl, S, Hewitt, SM, Badve, S, Symmans, WF, Kim, RS, Pruneri, G, Goel, S, Francis, PA, Inurrigarro, G, Yamaguchi, R, Garcia-Rivello, H, Horlings, H, Afqir, S, Salgado, R, Adams, S, Kok, M, Dieci, MV, Michiels, S, Demaria S, Loi, S, International Immuno-Oncology Biomarker Working Group

Publicado 2021

Enlace

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) t...